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Abstract Rationale: Nighttime agitation occurs fre-
quently in patients with dementia and represents the
number one burden on caregivers today. Current
treatment options are few and limited due to
substantial side effects. Objectives: The aim of the
study was to measure the effect of the cannabinoid
dronabinol on nocturnal motor activity. Methods: In
an open-label pilot study, six consecutive patients in
the late stages of dementia and suffering from
circadian and behavioral disturbances—five patients
with Alzheimer’s disease and one patient with vascu-
lar dementia—were treated with 2.5 mg dronabinol
daily for 2 weeks. Motor activity was measured
objectively using actigraphy. Results: Compared to
baseline, dronabinol led to a reduction in nocturnal
motor activity (P=0.028). These findings were corrob-
orated by improvements in Neuropsychiatric Inventory
total score (P=0.027) as well as in subscores
for agitation, aberrant motor, and nighttime
behaviors (P<0.05). No side effects were observed.
Conclusions: The study suggests that dronabinol was
able to reduce nocturnal motor activity and agitation
in severely demented patients. Thus, it appears that
dronabinol may be a safe new treatment option for
behavioral and circadian disturbances in dementia.
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Introduction
Behavioral symptoms and day–night rhythm disturbances
are frequent in patients with Alzheimer’s disease (AD).
Indeed, 50% of AD patients suffer from agitation and 25%
from aggressive behavior (Tariot 1999). Motor activity and
agitation during the night are higher in AD patients than in
healthy controls (Volicer et al. 2001), and approximately
50% of patients with severe AD develop day–night rhythm
disturbances or agitated behavior during the evening hours
(i.e., so-called sundowning; Hope et al. 1999). These
symptoms can become a great burden to professional
caregivers and family members. In fact, rhythm distur-
bances and sundowning are the number one cause of long-
term hospitalization in AD patients (Hebert et al. 2001).
Current treatment options include the use of benzodiaze-
pines and neuroleptics. However, these drugs have a
variety of adverse effects and often fail to reduce the
behavioral disturbances in question (Ballard et al. 2004;
Doody et al. 2001; Lee et al. 2004; Tariot et al. 2004).
Dronabinol (delta-9-tetrahydrocannabinol) is a CB1
receptor agonist (Howlett et al. 2002). This receptor is
expressed in many regions of the brain, including the
hippocampus, neocortex, basal ganglia, and the cerebellum
(Wilson and Nicoll 2002). CB1 receptors mediate im-
portant brain functions, including nociception, cognition,
motor activity, and mood (Breivogel and Childers 1998).
Cannabinoids may even prevent AD pathology as CB1
agonists have been shown to block microglial activation in
vivo (Ramirez et al. 2005). Animal models suggest that
CB1 receptor agonists may have a positive effect on sleep
architecture (Murillo-Rodriguez et al. 2003). CB1 receptor
agonists are currently used in the treatment of Tourette’s
syndrome (Muller-Vahl et al. 2003a,b), multiple sclerosis
(Svendsen et al. 2004), pain (Campbell et al. 2001), and
nausea in patients receiving chemotherapy (Tramer et al.
2001). One preliminary study has indicated that dronabinol
may be effective in alleviating anorexia and behavioral
disturbances in AD patients (Volicer et al. 1997). To date,
however, biometric instruments have not been used to
corroborate such findings. Wrist actigraphy, a valuable and
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objective means of obtaining data on motor activity and
circadian rhythms, has been shown to be a valid method for
measuring sleep–wake rhythms in patients with dementia
(Ancoli-Israel et al. 1997; Mahlberg et al. 2004). The aim
of our study was, thus, to apply this technique to obtain the
first objective data on the effects of dronabinol on
behavioral and day–night rhythm disturbances in dementia.
We hypothesized that, by means of sleep induction and its
effects on emotion, dronabinol would lead to less agitated
behavior in AD patients at night.
Methods
Patients
Six consecutive inpatients at our geriatric psychiatry unit
who had been diagnosed with dementia accompanied by
nighttime agitation, day–night rhythm disturbances, or
sundowning were included in this open-label trial. Patients’
guardians provided informed consent. The study was
conducted in accordance with the Declaration of Helsinki
and approved by the ethics committee of Charité
Universitätsmedizin Berlin. The four women and two
men had a mean age of 81.5 years (SD=6.1). The severity
of disease was rated using the Functional Assessment
Staging Tool (FAST) (Sclan and Reisberg 1992) and the
Mini Mental State Examination (MMSE) (Folstein et al.
1975). The mean FAST and MMSE scores were 5.67
(SD=0.52) and 10.33 (SD=6.28), respectively.
To be included in the study, patients had to meet
diagnostic criteria for dementia according to DSM-IV
(American Psychiatric Association 1994) and the National
Institute of Neurological and Communicative Disorders
and Stroke–Alzheimer’s Disease and Related Disorders
Association (NINCDS-ADRDA) (McKhann et al. 1984).
Five patients were diagnosed with probable dementia of the
Alzheimer’s type and one with probable vascular dementia.
To participate in the trial, patients also had to be in stable
medical condition. All prestudy medication for medical or
psychiatric illnesses was kept unchanged for at least 1 week
prior to the trial, as well as during the trial itself. Prestudy
medication included allopurinol, aspirin, angiotensin-con-
verting enzyme inhibitors, diuretics, statins, thyroxine, H2
blockers, insulin, digitoxine, or isosorbide dinitrate
(ISDN). Four patients had been taking psychiatric drugs
before the trial and continued to do so for the length of the
study; these included risperidone, carbamazepine, done-
pezil, galantamine, mirtazapine, or chloral hydrate. As
additional medication, patients were allowed to take
lorazepam 1 mg, clomethiazole 250 mg, or pipamperone
40 mg up to three times per day. Each dose was counted as
one unit of additional medication.
Measurements
Continuous recording of motor activity was initiated
immediately after hospital admission using a wrist
actometer (Actiwatch, Cambridge Neurotechnology Co.,
UK) worn on the patient’s nondominant arm. Patients wore
the same actometer for the length of the study. The
actometer uses an accelerometer which produces voltage
when the device is moved. Inside the sensor, the degree and
force of the movements are converted into activity counts,
which are then recorded. Movement counts were performed
every minute for the entire length of the trial. Motor activity
counts were calculated for three time periods: the nocturnal
period (9 PM–6 AM), the diurnal period (6 AM–9 PM), and the
evening period (3 PM–9 PM). Before entering the trial,
baseline scores were assessed using the Neuropsychiatric
Inventory (NPI) (Cummings et al. 1994). At the end of the
treatment, the NPI assessment was repeated. All ratings
were made by one investigator (SW).
Procedure
After 2 days of baseline assessments, patients received
2.5 mg dronabinol (MARINOL capsules, UNIMED
Pharmaceuticals, Inc., USA) every night at 7 PM for 2
weeks. The time of administration was set at 7 PM because
oral dronabinol has been shown to exert its initial effects
30–90 min after ingestion, with maximum plasma levels
being reached after 2–3 h; the effects of the medication can
last as long as 12 h, depending on the dose administered
(Grotenhermen 2003).
Analysis
The primary outcome measure was the reduction in
nocturnal motor activity during the last five nights of the
treatment period compared to the two nights at baseline, as
measured by actigraphy. The secondary outcome measures
were NPI total score and NPI subscores for nighttime
behaviors, delusions, and hallucinations. For further com-
parison, relative changes in nocturnal activity were
calculated by dividing the activity at the end of the
treatment period by the activity at baseline. Significant
differences were explored within paired groups using the
Wilcoxon signed rank test. The level of two-tailed
significance was set at P<0.05.
Results
No adverse events occurred during the study. The average
number of additional medications per day during the trial
was 0.93 units (SD=0.86). Three patients received less
units per day during treatment compared to baseline, while
three patients had a slight increase in additional medica-
tion. Thus, the amount and frequency of additional
medication did not change significantly between baseline
(M=1.04 units per day, SD=0.66) and treatment with
dronabinol (M=0.92 units per day, SD=0.77, z=−0.946,
P=0.406). Motor activity is shown in the Table 1. After
14 days of dronabinol treatment, nocturnal motor activity
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had decreased from baseline in all subjects (P=0.028; see
also Fig. 1); the average relative reduction in nocturnal
motor activity was 59% from baseline (range 13–85%).
This reduction was already evident during the first 2 days
of treatment (see Fig. 2). There were no significant changes
in any of the other actigraphic parameters (see Table 1 and
Fig. 2).
Not only was the NPI total score lower at the end of the
dronabinol treatment period (z=−2.207, P=0.027), but the
NPI subscores also revealed significant reductions in
aberrant motor behavior (z=−2.032, P=0.042), agitation
(z=−2.032, P=0.042), and nighttime behaviors (z=−2.032,
P=0.042). Exploratory testing showed that appetite dis-
turbances (z=−2.060, P=0.039) and irritability (z=−2.023,
P=0.043) were reduced as well. In addition, a trend towards
a reduction in anxiety was observed. The subscore for
delusions, apathy, and hallucinations did not change during
dronabinol treatment.
Discussion
For the first time, objective measures have been used to
show that the short-term administration of dronabinol may
be an effective treatment option in patients with severe
dementia who are suffering from behavioral and day–night
Table 1 Motor activity data at baseline and end of 14 days of treatment with 2.5 mg dronabinol
Patient Activity counts (103)
Diurnal (6 AM–9 PM) Evening (3 PM–9 PM) Nocturnal (9 PM–6 AM)
Baseline End Baseline End Baseline End
1 80.11 35.63 40.50 16.77 24.29 3.76
2 92.30 113.51 36.04 63.28 37.72 32.89
3 99.14 26.97 47.78 14.80 53.99 10.16
4 57.19 50.74 27.61 21.72 19.90 9.52
5 185.88 228.18 100.24 122.99 80.92 31.07
6 116.56 78.12 83.81 32.65 30.80 11.42
Median 95.72 64.42 44.14 27.19 34.26 10.79
SEa 18.05 30.69 11.89 17.15 9.31 5.03
Zb −0.943 −0.943 −2.201
P (2-tailed) 0.345 0.345 0.028*
*P<0.05
aStandard error
bWilcoxon signed rank test (two-tailed) of actimetric activity. Two days of baseline compared to last 5 days of treatment
Fig. 1 Effects of 14 days of
dronabinol treatment (2.5 mg at
7 PM) on nocturnal motor activ-
ity in patients with agitation in
severe dementia. *Wilcoxon
signed rank test
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rhythm disturbances. The reduction in nighttime motor
activity was already apparent after the first dose of
dronabinol. It remains to be seen whether these effects
are due to sleep induction via the CB1 receptor (Murillo-
Rodriguez et al. 2003).
Naturally, the results of the present study are prelimi-
nary. We chose, for example, to test a low dose of
dronabinol because of the general differences in pharma-
cokinetics between younger and older individuals. In
addition, although our patients were in stable medical
condition at the time of the trial, some of them had
substantial comorbidities, such as moderate heart or kidney
disease. Earlier trials of oral dronabinol have reported dose-
dependent side effects, including drowsiness, dizziness,
dysphoria, hypotension, hallucinations, headaches, and
palpitations (Campbell et al. 2001; Svendsen et al. 2004;
Tramer et al. 2001; Volicer et al. 1997). It is reassuring to
note that we were unable to observe any side effects due to
dronabinol or any aggravation of heart or kidney disease in
our patients. As a result, it is possible that higher doses of
dronabinol may be safe and lead to even better results.
Finally, for ethical reasons, we chose not to conduct the
study in a double-blinded, controlled fashion at this time.
NPI ratings were performed by the same rater and may thus
be biased by subjective perception. The actimetric data,
however, were obtained objectively.
Our trial has several important limitations. First, the
sample size of this pilot study was very small. Second,
although any prestudy psychotropic drugs were kept
unchanged for at least 1 week prior to the trial, as well as
during the trial itself, it is conceivable that they contributed
to the reduction we observed in psychomotor activity.
Third, we did not measure the effects of dronabinol on
cognition or function in this trial. In a recent study on the
use of dronabinol in patients with Tourette’s syndrome, no
influence on neuropsychological function was observed
(Muller-Vahl et al. 2003a). In very elderly patients with
severe illnesses, however, dronabinol might potentially
lead to a deterioration in cognition and function. Clinically,
we were unable to observe this effect in our patients.
However, because we did not measure the effects on
cognition or function over the course of treatment, such
side effects cannot be ruled out.
Others have suggested that dronabinol may have a
favorable impact on anorexia and disturbed behavior in
patients with Alzheimer’s disease (Volicer et al. 1997). The
biometric data obtained in the present study corroborate
these findings. We suspect that controlled clinical trials will
reveal dronabinol to have beneficial effects in severely
demented patients. Indeed, dronabinol may prove to be a
new treatment option for these individuals and help prevent
costly long-term hospitalizations.
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